Clinical Study Of Therapeutic Effect And Prognosis On Advanced Breast Cancer Of Different Molecular Subtypes Treated With Newadjuvant Chemotherapy

Part 1:The effect of neoadjuvant chemotherapy on advanced breast cancer of different molecular subtypesObjective:To investigate the effect of epirubicin combined with docetaxel on advanced breast cancer of different molecular subtypes.Methods:We evaluated 83 patients with advanced breast cancer, who experienced 2-6 cycles of neoadjuvant chemotherapy, to know the effects of neoadjuvant chemotherapy.Result:The Response rate is 81.9%(68/83). pathologic complete response is 8.4%(7/83). clinical complete response is 14.5%(12/83). partial response is 59.0%(49/83), stable disease is 18.1%(15/83). and there is no PD cases.The effect of neoadjuvant chemotherapy is associated with different subtypes, there is no difference in PCR and CCR of different molecular subtypes。The response rate and pathologic complete response of subtype of ERBB2+ and subtype of Basal-like is higher than that of subtype of Luminal.Conclusion:when the chemotherapy is epirubicin combined with docetaxel, the subtype of breast cancer can be regarded as a predictor of prognosis, of which the subtype of ERBB2+ and subtype of Basal-like benefits more.Part 2:Predictors of neoadjuvant chemotherapy effect on advanced breast cancerObjective:To investigate predictors of neoadjuvant chemotherapy effect on advanced breast cancer.Methods:In this research,83 patients with locally advanced or metastases breast cancer experienced 2-6 cycles of neoadjuvant chemotherapy.we investigated the relationship between effects of chemotherapy and changes of expression of ER、PR、HER-2 and Ki-67.Results:The changes of ER、Ki-67 showed significant difference. The group of ki-67 positive and group of ki-67 negative showed significant difference in pCR+cCR and PR+SD.Conclusion:The changes of ER and ki-67 is associated with chemotherapy effect, the high expression of ki-67 can be a sensitive predictor of effect of neoadjuvant chemotherapy.Part 3:the relationship of prognosis between molecular subtypes and therapeutic effect of breast cancer patients treated with neoadjuvant chemotherapyObjective:To investigate the relationship of prognosis between molecular subtypes and therapeutic effect of breast cancer patients treated with neoadjuvant chemotherapy.Methods:83 cases of advanced breast cancer patients were followed up for 29 months. to evaluate the disease-free survival and overall survival, and to study the relationship of prognosis between molecular subtypes and therapeutic effect.Results:There was no significant difference in overall survival and disease-free survival among different molecular subtypes (x2=3.390,p=0.335和χ2=2.183,p=0.535) Among patients with different curative effect there was no significant difference in t overall survival (x2=2.801, p=0.423). diseas-free survival was statistically significant (χ2=8.588, p=0.035). patients with cCR were better than PR (x2=4.064,p=0.044).Conclusion:There is no difference in the overall survival of advanced breast cancer in 29 months. The different effects of neoadjuvant chemotherapy will affect diseas-free survival of patients.